series-a
Stage
About
Neowisebio develops TCR-T immunotherapy drugs for solid tumor patients by utilizing a highly sensitive target-TCR discovery and validation platform, aiming to expand treatment targets and options for cancer patients.
Explore Neowisebio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.